Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials
The association between glucagon-like peptide-1 (GLP-1) receptor agonists and the risk of various kinds of thyroid disorders remains uncertain. We aimed to evaluate the relationship between the use of GLP-1 receptor agonists and the occurrence of 6 kinds of thyroid disorders. We searched PubMed (MED...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.927859/full |
| _version_ | 1811219109492293632 |
|---|---|
| author | Weiting Hu Rui Song Rui Cheng Caihong Liu Rui Guo Wei Tang Jie Zhang Qian Zhao Xing Li Jing Liu |
| author_facet | Weiting Hu Rui Song Rui Cheng Caihong Liu Rui Guo Wei Tang Jie Zhang Qian Zhao Xing Li Jing Liu |
| author_sort | Weiting Hu |
| collection | DOAJ |
| description | The association between glucagon-like peptide-1 (GLP-1) receptor agonists and the risk of various kinds of thyroid disorders remains uncertain. We aimed to evaluate the relationship between the use of GLP-1 receptor agonists and the occurrence of 6 kinds of thyroid disorders. We searched PubMed (MEDLINE), EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science from database inception to 31 October 2021 to identify eligible randomized controlled trials (RCTs). We performed meta-analysis using a random-effects model to calculate risk ratios (RRs) and 95% confidence intervals (CIs). A total of 45 trials were included in the meta-analysis. Compared with placebo or other interventions, GLP-1 receptor agonists’ use showed an association with an increased risk of overall thyroid disorders (RR 1.28, 95% CI 1.03-1.60). However, GLP-1 receptor agonists had no significant effects on the occurrence of thyroid cancer (RR 1.30, 95% CI 0.86-1.97), hyperthyroidism (RR 1.19, 95% CI 0.61-2.35), hypothyroidism (RR 1.22, 95% CI 0.80-1.87), thyroiditis (RR 1.83, 95% CI 0.51-6.57), thyroid mass (RR 1.17, 95% CI 0.43-3.20), and goiter (RR 1.17, 95% CI 0.74-1.86). Subgroup analyses and meta-regression analyses showed that underlying diseases, type of control, and trial durations were not related to the effect of GLP-1 receptor agonists on overall thyroid disorders (all P subgroup > 0.05). In conclusion, GLP-1 receptor agonists did not increase or decrease the risk of thyroid cancer, hyperthyroidism, hypothyroidism, thyroiditis, thyroid mass and goiter. However, due to the low incidence of these diseases, these findings need to be examined further.Systematic Review RegistrationPROSPERO https://www.crd.york.ac.uk/prospero/, identifier: CRD42021289121. |
| first_indexed | 2024-04-12T07:19:46Z |
| format | Article |
| id | doaj.art-d1bb4c57954640a4a00e3fd1dd6952e3 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-12T07:19:46Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-d1bb4c57954640a4a00e3fd1dd6952e32022-12-22T03:42:22ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-07-011310.3389/fendo.2022.927859927859Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled TrialsWeiting Hu0Rui Song1Rui Cheng2Caihong Liu3Rui Guo4Wei Tang5Jie Zhang6Qian Zhao7Xing Li8Jing Liu9The Second Clinical Medical College, Shanxi Medical University, Taiyuan, ChinaThe Second Clinical Medical College, Shanxi Medical University, Taiyuan, ChinaDepartment of Endocrinology, Second Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Physiology, Shanxi Medical University, Taiyuan, ChinaDepartment of Physiology, Shanxi Medical University, Taiyuan, ChinaDepartment of Endocrinology, Second Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Endocrinology, Second Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Endocrinology, Second Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Endocrinology, Second Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Endocrinology, Second Hospital of Shanxi Medical University, Taiyuan, ChinaThe association between glucagon-like peptide-1 (GLP-1) receptor agonists and the risk of various kinds of thyroid disorders remains uncertain. We aimed to evaluate the relationship between the use of GLP-1 receptor agonists and the occurrence of 6 kinds of thyroid disorders. We searched PubMed (MEDLINE), EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science from database inception to 31 October 2021 to identify eligible randomized controlled trials (RCTs). We performed meta-analysis using a random-effects model to calculate risk ratios (RRs) and 95% confidence intervals (CIs). A total of 45 trials were included in the meta-analysis. Compared with placebo or other interventions, GLP-1 receptor agonists’ use showed an association with an increased risk of overall thyroid disorders (RR 1.28, 95% CI 1.03-1.60). However, GLP-1 receptor agonists had no significant effects on the occurrence of thyroid cancer (RR 1.30, 95% CI 0.86-1.97), hyperthyroidism (RR 1.19, 95% CI 0.61-2.35), hypothyroidism (RR 1.22, 95% CI 0.80-1.87), thyroiditis (RR 1.83, 95% CI 0.51-6.57), thyroid mass (RR 1.17, 95% CI 0.43-3.20), and goiter (RR 1.17, 95% CI 0.74-1.86). Subgroup analyses and meta-regression analyses showed that underlying diseases, type of control, and trial durations were not related to the effect of GLP-1 receptor agonists on overall thyroid disorders (all P subgroup > 0.05). In conclusion, GLP-1 receptor agonists did not increase or decrease the risk of thyroid cancer, hyperthyroidism, hypothyroidism, thyroiditis, thyroid mass and goiter. However, due to the low incidence of these diseases, these findings need to be examined further.Systematic Review RegistrationPROSPERO https://www.crd.york.ac.uk/prospero/, identifier: CRD42021289121.https://www.frontiersin.org/articles/10.3389/fendo.2022.927859/fullGLP-1 receptor agoniststhyroid disordersthyroid cancermeta-analysisrandomized controlled trials |
| spellingShingle | Weiting Hu Rui Song Rui Cheng Caihong Liu Rui Guo Wei Tang Jie Zhang Qian Zhao Xing Li Jing Liu Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials Frontiers in Endocrinology GLP-1 receptor agonists thyroid disorders thyroid cancer meta-analysis randomized controlled trials |
| title | Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials |
| title_full | Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials |
| title_fullStr | Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials |
| title_full_unstemmed | Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials |
| title_short | Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials |
| title_sort | use of glp 1 receptor agonists and occurrence of thyroid disorders a meta analysis of randomized controlled trials |
| topic | GLP-1 receptor agonists thyroid disorders thyroid cancer meta-analysis randomized controlled trials |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.927859/full |
| work_keys_str_mv | AT weitinghu useofglp1receptoragonistsandoccurrenceofthyroiddisordersametaanalysisofrandomizedcontrolledtrials AT ruisong useofglp1receptoragonistsandoccurrenceofthyroiddisordersametaanalysisofrandomizedcontrolledtrials AT ruicheng useofglp1receptoragonistsandoccurrenceofthyroiddisordersametaanalysisofrandomizedcontrolledtrials AT caihongliu useofglp1receptoragonistsandoccurrenceofthyroiddisordersametaanalysisofrandomizedcontrolledtrials AT ruiguo useofglp1receptoragonistsandoccurrenceofthyroiddisordersametaanalysisofrandomizedcontrolledtrials AT weitang useofglp1receptoragonistsandoccurrenceofthyroiddisordersametaanalysisofrandomizedcontrolledtrials AT jiezhang useofglp1receptoragonistsandoccurrenceofthyroiddisordersametaanalysisofrandomizedcontrolledtrials AT qianzhao useofglp1receptoragonistsandoccurrenceofthyroiddisordersametaanalysisofrandomizedcontrolledtrials AT xingli useofglp1receptoragonistsandoccurrenceofthyroiddisordersametaanalysisofrandomizedcontrolledtrials AT jingliu useofglp1receptoragonistsandoccurrenceofthyroiddisordersametaanalysisofrandomizedcontrolledtrials |